The Senate Committee on Health, Education, Labor and Pensions grilled Novo Nordisk’s CEO Lars Fruergaard Jørgensen on the company’s high price for its  weight loss drugs Ozempic and Wegovy in the United States compared to other countries.

Jørgensen never directly answered the question posed by Senate HELP Committee Chairman Sen. Bernie Sanders (I-Vt.) several times: Why do the drugs cost nine times as much in the United States as they do in Germany?